Tyroservatide
Alternative Names: CMS-024-02Latest Information Update: 08 Jan 2016
At a glance
- Originator China Medical System; Shenzhen Kangzhe Pharmaceutical
- Developer Shenzhen Kangzhe Pharmaceutical
- Class Antineoplastics; Oligopeptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 31 Mar 2007 CMS files an application for approval of a phase II trial with China's State FDA for non-small lung cancer
- 30 Nov 2006 CMS completes a phase I trial in non-small cell lung cancer in China
- 31 Mar 2006 Phase-I clinical trials in Non-small cell lung cancer in China (Parenteral)